GIP; GLP-1 and glucagon receptor tri-agonist
Retatrutide injection
RETA_SC
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -6.67 (-13.08 to -0.74) | 0.91 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -7.35 (-12.44 to -2.20) | 0.87 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.27 (0.43 to 4.36) | 0.39 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.41 (1.32 to 8.97) | 0.30 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.13 (0.66 to 7.70) | 0.46 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.23 (1.17 to 10.81) | 0.20 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -11.97 (-18.17 to -4.48) | 0.92 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -15.35 (-22.79 to -6.79) | 0.66 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.90 (0.25 to 4.03) | 0.63 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.04 (1.51 to 7.00) | 0.55 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.22 (1.61 to 60.33) | 0.37 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.24 (0.49 to 3.26) | 0.68 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.83 (1.07 to 21.46) | 0.26 |
Trials
- NCT04867785A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes2021 · 281 randomized · 36 weeks
- NCT04881760A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities2021 · 338 randomized · 48 weeks